Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPAN: Adrulipase in CF EPI
NCT05719311Phase 2Completed
- Sponsor
- Entero Therapeutics, Inc.
- Start
- Feb 2023
- Primary completion
- Jun 2023
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adrulipase alfa in exocrine pancreatic insufficiency (EPI), sponsored by Entero Therapeutics, Inc. Primary endpoints: Safety of Adrulipase at 3 weeks and Coefficient of Fat Absorption at 3 weeks. Started Feb 2023; status: completed.
02
Drugs
adrulipase alfa
03
Conditions
exocrine pancreatic insufficiency (EPI)
Beyond the preview
Go deeper on NCT05719311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05719311.